MedTrace Logo

Stereotactic Radiotherapy in Association With Immunotherapy for the Treatment of NSCLC Brain Metastases

NCT04787185 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-03-08

No results posted yet for this study

Summary

The study's primary objective is the evaluation of toxicities reported during RS or HFSRT in patients with brain metastases from NSCLC undergoing immunotherapy (Safety), with particular reference to the rate of symptomatic radionecrosis and intralesional hemorrhage. Others primary objectives of the study are the Feasibility and the intracranial control of the disease, both local (site radiotherapy treatment) and at a distance (intracranial, but at a distance from the site of the disease treated with stereotaxic radiotherapy). The secondary objectives concern quality assessment of life of the patients under study (Quality Of Life, QoL).

Conditions

  • Brain Metastases From NSCLC

Interventions

RADIATION

Valutation of toxicity

Observation of toxicity All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria Careggi

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-17
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04787185 on ClinicalTrials.gov